Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02913105 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT02913105 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT02913105, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
Interventions
- DRUG Placebo
- DRUG LMB763
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-10-24 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02913105
The ClinicalTrials.gov registry entry for NCT02913105 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02913105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02913105 about?
NCT02913105 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH". The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
What is the current status of trial NCT02913105?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2016-10-24. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT02913105?
The interventions under investigation include: Placebo (DRUG), LMB763 (DRUG).
Who is sponsoring clinical trial NCT02913105?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.